Yuhan signs license agreement for new hepatitis B treatment

Published: 2011-04-01 06:59:00

Updated: 2011-04-01 06:59:00

Yuhan Corp. said Wednesday that the company has concluded an agreement with the U.S.-based Gilead Sciences Inc., under which Yuhan will have an exclusive right to market Viread (tenofovir disoproxil fumarate) for treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK